Analyst Upgrades

• Wunderlich upgraded Granite Construction (GVA) to buy from hold, citing valuation and expected positive catalysts in 2011. The firm has a $29 price target for shares.
• Jefferies upgraded WuXi PharmaTech (WX) to buy from hold following the Q2 report, citing continued strength in China-based lab services growth. The firm has an $18 target on shares.
• BMO Capital upgraded Newell Rubbermaid (NWL) to outperform from market perform following capital structure actions. The firm has a $20 price target on the stock.
• Energizer (ENR) was upgraded to overweight from equal weight at Morgan Stanley.
• Cephalon (CEPH) was upgraded to buy from neutral at BofA/Merrill.
• Dycom (DY) was upgraded to outperform from market perform at Morgan Keegan.

MOST NOTEWORTHY: Solarfun Power, BioMarin Pharmaceutical and Genentech were today's noteworthy initiations:

• Jefferies initiated Solarfun Power (NASDAQ:SOLF) with a Buy rating and $18 target. The firm believes the one-third stake purchased by Good Energies and new management hires could generate operational momentum and that declining silicon costs may help margins.
  
• BioMarin Pharmaceutical (NASDAQ:BMRN) was started at Oppenheimer with a Perform rating. The firm recommends waiting for Street estimates on Kuvan sales to moderate and for positive pipeline signals before adding to positions.
  
• Genentech (NYSE:DNA) was initiated at Citigroup with a Buy rating and $91 target. The firm believes several studies could lead to robust growth and points out the company's Q2 results showed Avastin reaccelerating due to growth in breast cancer.

OTHER INITIATIONS:

• Goldman reinstated Staples (NASDAQ:SPLS) with a Neutral rating.
  
• Zebra Tech (NASDAQ:ZBRA) was initiated with a Hold rating at KeyBanc.
  
• Rodman & Renshaw assumed coverage of Corcept Therapeutics (NASDAQ:CORT) with an Outperform rating and $8 target.
  
• AuthenTec (NASDAQ:AUTH) was initiated at JP Morgan with an Overweight rating and at Canaccord Adams with a Hold rating and $10 target.

MOST NOTEWORTHY: Lubrizol, BioMarin Pharmaceutical and Novartis were today's noteworthy downgrades:

• Jefferies downgraded shares of Lubrizol (NYSE:LZ) to Hold from Buy as they expect persistent raw material cost pressures to limit upside over the next few quarters. The firm lowered their target price to $60 from $65.
  
• Citigroup cut BioMarin (NASDAQ:BMRN) to Hold from Buy after their survey indicated an upside surprise from the Kuvan launch is unlikely. The firm lowered their target price to $37 from $42.
  
• HSBC downgraded shares of Novartis (NYSE:NVS) to Underweight from Neutral following the company's stake in Alcon (NYSE:ACL) as they believe it dilutes the company's return on assets.

OTHER DOWNGRADES:

• Goldman removed Waste Management (NYSE:WMI) from its Conviction Buy List.
  
• Thomas Weisel downgraded Kinross Gold (NYSE:KGC) to Market Weight from Overweight.
  
• Dreamworks Animation (NYSE:DWA) was lowered at UBS to Sell from Neutral.
  
• JP Morgan downgraded Martha Stewart (NYSE:MSO) to Neutral from Overweight.